According to data from a phase II study, the anti-HER2 combination of trastuzumab and lapatinib is active in patients with KRAS–wild-type, HER2-positive metastatic colorectal cancer. None of the study participants responded to previous, standard treatment with the EGFR inhibitors cetuximab or panitumumab, but 30% achieved an objective response to dual HER2 blockade.
from Cancer via ola Kala on Inoreader http://ift.tt/296vfma
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου